MedTrace Logo

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

NCT06348134 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2026-02-17

No results posted yet for this study

Summary

Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery.

Conditions

Interventions

DRUG

Trastuzumab emtansine

A chemotherapy drug.

DRUG

Pertuzumab Injection

A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

DRUG

Docetaxel

A chemotherapy drug.

DRUG

Tamoxifen

A medication used to treat breast cancer.

DRUG

Letrozole

A medication used to treat breast cancer.

DRUG

Goserelin

A hormone therapy drug.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Olufunmilayo Olopade · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-18
Primary Completion
2034-07-01
Completion
2036-07-01

Countries

  • Nigeria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06348134 on ClinicalTrials.gov